Last updated: April 24, 2026
Who Supplies Sunitinib Malate to the Market?
Sunitinib malate is a widely sourced oncology API with a mature generic landscape. The supplier set spans (1) originator-grade and branded supply chains and (2) multiple ANDA/authorized-generic and bulk-API makers that sell into distributors, contract manufacturers, and finished-dose packagers.
What is the drug and what form do suppliers sell?
- INN (active): Sunitinib
- Salt form (commercial API): sunitinib malate
- Drug product example: sunitinib malate tablets (most commonly referenced in commercial supply)
- Supplier scope in practice:
- API manufacturers (bulk “sunitinib malate”)
- intermediates producers (for contract API synthesis)
- finished-dose packagers and marketers that source API from API suppliers and sell tablets under NDCs/MAHs
Which supplier categories matter for procurement?
1) API manufacturers
These suppliers provide the material used to manufacture finished tablets or other dosage forms. API sourcing is typically the biggest driver of cost, lead time, and regulatory friction.
2) Finished-dose manufacturers (MAHs)
These companies buy compliant API, manufacture tablets, and sell finished product to wholesalers, hospitals, and tenders.
3) Distributors and contract manufacturers
These entities move supply from API and tablet manufacturers to end users. They rarely control the molecule-level quality attributes but often control documentation flow (CoA, stability, DMF/ASMF linkage, chain-of-custody).
What are the major known manufacturing networks for sunitinib malate?
Which countries dominate sunitinib malate supply?
- India: largest cluster of generic API and finished-dose production for oncology small molecules
- China: major API and intermediate capacity for oncology agents
- Europe/US: originator and authorized supply chains; fewer API makers relative to Asia, but more finished-dose brand and generic packaging operations
(Commercial sourcing for sunitinib malate typically routes through these hubs; compliance documentation and DMF/ASMF access are the gating items.)
What supplier lists are typically used in R&D and tendering?
Common procurement inputs suppliers provide
- DMF/ASMF reference (where applicable) for API regulatory linkage
- CEP (if held) for salt form and polymorph control (where applicable)
- particle size and polymorph documentation for sunitinib malate
- residual solvents and heavy metals specs per ICH-aligned methods
- impurities profile for sunitinib and known degradants
How do suppliers differentiate sunitinib malate supply?
Key quality and compliance levers
- Salt form consistency: sunitinib malate grade control (water content, conversion behavior)
- Polymorph control: demonstrated via XRPD/DSC where supplied
- Impurities: control of process-related impurities and degradation products
- Regulatory package alignment: DMF/ASMF access and audit history
What are the actionable next steps for identifying specific named suppliers?
What procurement teams typically do
- Use regulatory status and listing databases (API DMF, ASMF holders, and finished-dose product labels) to extract named manufacturing sites and MAHs.
- Cross-check facility names against:
- GMP inspections and warning letter history
- recent batch CoA availability
- supply continuity for the relevant market (US/EU/other)
Key Takeaways
- Sunitinib malate sourcing is dominated by Asia-based API and generic finished-dose networks, with regulatory documentation (DMF/ASMF, polymorph control, impurities) as the key procurement filter.
- Supplier selection hinges on regulatory linkage and batch-to-batch quality documentation, not just price.
- For named suppliers, the most reliable route is extracting manufacturing sites and MAHs from regulatory listing records, then validating with CoA and GMP audit posture.
FAQs
1) Is sunitinib malate sourced as API or finished tablets?
It is commonly procured as API for tablet manufacturing and also as finished tablets via MAHs for direct distribution.
2) Which type of supplier is the primary cost driver?
API suppliers usually drive the largest portion of raw material cost and indirectly affect finished-dose manufacturing yield and stability.
3) What documents matter most when qualifying an API supplier for sunitinib malate?
DMF/ASMF linkage, CoA, impurity profile, and salt/polymorph controls are typically the qualification core.
4) Do suppliers carry multiple grades of sunitinib malate?
Yes. Commercial supply often distinguishes grades by regulatory pathway, impurity limits, and evidence of salt form/polymorph control.
5) What countries supply most sunitinib malate commercially?
Commercial capacity is concentrated in India and China, with Europe and the US contributing more to branded and packaging supply chains.
References (APA)
[1] European Medicines Agency (EMA). (n.d.). EPAR: Sutent. https://www.ema.europa.eu/
[2] U.S. Food and Drug Administration (FDA). (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
[3] U.S. Food and Drug Administration (FDA). (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
